Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Hanley

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|April 16, 2019
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency DisordersShabnum Patel, Haili Lang, Gelina Sani, et al.
Cytotherapy|March 4, 2014
Low rate of infusional toxicity after expanded cord blood transplantationAdham S Bear, Patrick J Hanley, Doyle M Bosque, et al.
Transplantation and Cellular Therapy|February 3, 2023
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young AdultsThomas J Galletta, Adam Lane, Carolyn Lutzko, et al.
Journal for Immunotherapy of Cancer|December 2, 2025
Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recoveryMark D Stewart, Christopher R Cabanski, Jeff D Allen, et al.
Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.
Blood Advances|November 20, 2020
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipientsAdam S Nelson, Daria Heyenbruch, Jeremy D Rubinstein, et al.
Blood Advances|September 8, 2021
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphomaHema Dave, Madeline Terpilowski, Mimi Mai, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 21, 2024
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplantRuby Khoury, Michael S Grimley, Adam S Nelson, et al.
Blood|September 29, 2018
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantationLauren P McLaughlin, Rayne Rouce, Stephen Gottschalk, et al.
Molecular Therapy. Methods & Clinical Development|May 4, 2022
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy productsJessica Durkee-Shock, Christopher A Lazarski, Mariah A Jensen-Wachspress, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|April 16, 2019
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency DisordersShabnum Patel, Haili Lang, Gelina Sani, et al.
Cytotherapy|March 4, 2014
Low rate of infusional toxicity after expanded cord blood transplantationAdham S Bear, Patrick J Hanley, Doyle M Bosque, et al.
Transplantation and Cellular Therapy|February 3, 2023
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young AdultsThomas J Galletta, Adam Lane, Carolyn Lutzko, et al.
Journal for Immunotherapy of Cancer|December 2, 2025
Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recoveryMark D Stewart, Christopher R Cabanski, Jeff D Allen, et al.
Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.
Blood Advances|November 20, 2020
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipientsAdam S Nelson, Daria Heyenbruch, Jeremy D Rubinstein, et al.
Blood Advances|September 8, 2021
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphomaHema Dave, Madeline Terpilowski, Mimi Mai, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 21, 2024
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplantRuby Khoury, Michael S Grimley, Adam S Nelson, et al.
Blood|September 29, 2018
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantationLauren P McLaughlin, Rayne Rouce, Stephen Gottschalk, et al.
Molecular Therapy. Methods & Clinical Development|May 4, 2022
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy productsJessica Durkee-Shock, Christopher A Lazarski, Mariah A Jensen-Wachspress, et al.
Pageof 10